Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmHrpmIrpmJrpmJ2rpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsU
The experimentally established mechanism targets of Tobramycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.64 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | GJA1 | P17302 | 2/20 | 0.52 |
| ▸ | GJB2 | P29033 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tobramycin SCHEMBL3952941 | 0.84 | GAA (0.59) | GAAALOX15HPSECYP3A4MAPT | |
| Tobramycin SCHEMBL8343251 | 0.83 | GAA (0.63) | GAAALOX15HPSECYP3A4MAPT | |
| Tobramycin SCHEMBL1178021 | 0.82 | ALOX15 (0.87) | GAAALOX15HPSECYP3A4MAPT | |
| Tobramycin SCHEMBL1561126 | 0.81 | GAA (1.00) | GAAALOX15HPSECYP3A4MAPT | |
| Tobramycin SCHEMBL2837 | 0.81 | GAA (1.00) | GAAALOX15HPSECYP3A4MAPT | |
| Tobramycin SCHEMBL8573253 | 0.81 | GAA (1.00) | GAAALOX15HPSECYP3A4MAPT | |
| Tobramycin SCHEMBL9712239 | 0.81 | GAA (1.00) | GAAALOX15HPSECYP3A4MAPT | |
| Tobramycin SCHEMBL2637031 | 0.81 | GAA (1.00) | GAAALOX15HPSECYP3A4MAPT | |
| Tobramycin SCHEMBL3658310 | 0.80 | ALOX15 (1.00) | GAAALOX15HPSECYP3A4MAPT | |
| Tobramycin SCHEMBL12930900 | 0.80 | ALOX15 (1.00) | GAAALOX15HPSECYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3656374-A1 | OCULAR THERAPY USING ALPHA-2 ADRENERGIC RECEPTOR AGONISTS HAVING ENHANCED ANTERIOR CLEARANCE RATES | ALLERGAN, INC. (US) | 2020-05-27 | — | — | EP | disclosed |
| EP-1879553-B1 | OCULAR THERAPY USING ALPHA-2 ADRENERGIC RECEPTOR AGONISTS HAVING ENHANCED ANTERIOR CLEARANCE RATES | ALLERGAN INC (US) | 2020-02-12 | — | — | EP | disclosed |
| US-7931909-B2 | Combining an agonist with a liquid carrier or a polymer to administer to an eye, and determining the vitreous half-life and clearance of the drug; sustained drug delivery affecting the anterior or anterior/posterior eye segment; neuroprotection;antiischemic agents; glaucoma; vitreal half-life | ALLERGAN, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20080112923-A1 | OCULAR THERAPY USING ALPHA-2 ADRENERGIC RECEPTOR ANTERIOR COMPOUNDS HAVING ENHANCED CLEARANCE RATES | ALLERGAN, INC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080112922-A1 | OCULAR THERAPY USING ALPHA-2 ADRENERGIC RECEPTOR ANTERIOR COMPOUNDS HAVING ENHANCED CLEARANCE RATES | ALLERGAN, INC (US) | 2008-05-15 | — | — | US | disclosed |
| EP-1879553-A2 | OCULAR THERAPY USING ALPHA-2 ADRENERGIC RECEPTOR AGONISTS HAVING ENHANCED ANTERIOR CLEARANCE RATES | Allergan, Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060257452-A1 | Ocular therapy using alpha-2 adrenergic receptor anterior compounds having enhanced clearance rates | ALLERGAN, INC. (US) | 2006-11-16 | — | — | US | disclosed |
| WO-2006122165-A2 | OCULAR THERAPY USING ALPHA-2 ADRENERGIC RECEPTOR AGONISTS HAVING ENHANCED ANTERIOR CLEARANCE RATES | ALLERGAN, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080112922-A1 | OCULAR THERAPY USING ALPHA-2 ADRENERGIC RECEPTOR ANTERIOR COMPOUNDS HAVING ENHANCED CLEARANCE RATES | ADRB2, ADRA2A, ADRA2B | GAA 2212/4885ALOX15 1679/4885HPSE 2983/4885 |
| US-20080112923-A1 | OCULAR THERAPY USING ALPHA-2 ADRENERGIC RECEPTOR ANTERIOR COMPOUNDS HAVING ENHANCED CLEARANCE RATES | ADRB2, ADRA2A, ADRA2B | GAA 2212/4885ALOX15 1679/4885HPSE 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.